These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 21095445

  • 21. Calcineurin inhibitor-free protocols: risks and benefits.
    Barbari AG, Stephan AG, Masri MA.
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
    [Abstract] [Full Text] [Related]

  • 22. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F.
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [Abstract] [Full Text] [Related]

  • 23. Operational tolerance: past lessons and future prospects.
    Levitsky J.
    Liver Transpl; 2011 Mar; 17(3):222-32. PubMed ID: 21384504
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G, Srinivas TR, Meier-Kriesche HU.
    Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
    [Abstract] [Full Text] [Related]

  • 26. The role and value of sirolimus administration in kidney and liver transplantation.
    Mehrabi A, Fonouni H, Kashfi A, Schmied BM, Morath Ch, Sadeghi M, Schemmer P, Encke J, Sauer P, Zeier M, Weitz J, Büchler MW, Schmidt J.
    Clin Transplant; 2006 Oct; 20 Suppl 17():30-43. PubMed ID: 17100699
    [Abstract] [Full Text] [Related]

  • 27. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW, Chudzinski R.
    Transplantation; 2009 Jan 27; 87(2):164-5. PubMed ID: 19155968
    [No Abstract] [Full Text] [Related]

  • 28. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
    Nashan B.
    Clin Transplant; 2013 Jan 27; 27 Suppl 25():16-29. PubMed ID: 23909498
    [Abstract] [Full Text] [Related]

  • 29. Causes of sirolimus discontinuation in 97 liver transplant recipients.
    Panaro F, Piardi T, Gheza F, Ellero B, Audet M, Cag M, Cinqualbre J, Wolf P.
    Transplant Proc; 2011 May 27; 43(4):1128-31. PubMed ID: 21620069
    [Abstract] [Full Text] [Related]

  • 30. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D, Martínez D, Gutiérrez E, López V, Gutiérrez C, García P, Cobelo C, Cabello M, Burgos D, Sola E, González-Molina M.
    Nefrologia; 2011 May 27; 31(1):27-34. PubMed ID: 21270910
    [Abstract] [Full Text] [Related]

  • 31. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec 27; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 32. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years.
    Engelen MA, Amler S, Welp H, Vahlhaus C, Gunia S, Sindermann JR, Rothenburger M, Stypmann J.
    Transplantation; 2011 May 27; 91(10):1159-65. PubMed ID: 21478817
    [Abstract] [Full Text] [Related]

  • 33. [Low-toxicity immunosuppressive therapy in renal transplant].
    Scolari F, La Manna G, Comai G, Cappuccilli ML, Todeschini P, Ciavatti A, Persici E, Feliciangeli G, Stefoni S.
    G Ital Nefrol; 2007 May 27; 24 Suppl 38():44-8. PubMed ID: 17922447
    [Abstract] [Full Text] [Related]

  • 34. New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients.
    Sommerer C, Giese T, Meuer S, Zeier M.
    Saudi J Kidney Dis Transpl; 2010 Nov 27; 21(6):1030-7. PubMed ID: 21060169
    [Abstract] [Full Text] [Related]

  • 35. Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation.
    Danger R, Giral M, Soulillou JP, Brouard S.
    Curr Opin Organ Transplant; 2008 Dec 27; 13(6):609-13. PubMed ID: 19060551
    [Abstract] [Full Text] [Related]

  • 36. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE, Watson CJ, Gibbs P, Bradley JA, Ntzani EE, Kosmoliaptsis V.
    Transplantation; 2016 Mar 27; 100(3):621-9. PubMed ID: 26636736
    [Abstract] [Full Text] [Related]

  • 37. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F, Christians U, Smith L, Wellen JR, Kaplan B.
    Transpl Immunol; 2014 Jun 27; 31(1):22-32. PubMed ID: 24861504
    [Abstract] [Full Text] [Related]

  • 38. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.
    Transplantation; 2010 Apr 15; 89(7):864-72. PubMed ID: 20061999
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.